The Potential Role of Platelet-Activating Factor in Cancer Immunotherapy Background Cancer immunotherapy has been a significant breakthrough in cancer treatment in recent years, but its efficacy is still limited by the immunosuppressive mechanisms within the tumor microenvironment (TME). The TME supports the differentiation and proliferation of mye...

Synthetic Biology in Cancer Immunotherapy: Engineering Bacteria to Inhibit IDO Activity and Reprogram CD8+ T Cell Responses Academic Background In recent years, significant progress has been made in cancer immunotherapy, particularly through the activation of T cells to combat tumors. However, metabolic adaptations in the tumor microenvironment (TM...

Application of Base Editing Screening Technology in Tumor Immunotherapy T Cell Research Immune cell therapies, such as T cell transfer therapy and CAR T cell therapy, have become important clinical cancer treatment tools in certain disease fields. However, most cancer patients fail to benefit from cell therapies, possibly due to inherent changes in...

GRIN2A Mutations as a Novel Indicator for Stratifying Beneficiaries of Immune Checkpoint Inhibitors in Various Cancers Background Immune checkpoint inhibitors (ICIs) therapy, which modulates the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death (ligand) 1 (PD-(L)1) pathways, has made revolutionary progress in treating v...